Juno Therapeutics Inc. (NASDAQ:JUNO) [Trend Analysis] knocking active thrust in leading trading session, shares a gain of 3.50% to 39.68 with around 950719 shares have changed hands in this session. Juno Therapeutics, Inc. (JUNO) declared that in partnership with its collaborators it will present key clinical updates on its investigational products JCAR014, JCAR015 and JCAR017 at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting 2016 in Chicago, Illinois from June 3-7. JCAR014, JCAR015 and JCAR017 are chimeric antigen receptor (CAR) T cell product candidates that target CD19, a protein expressed on the surface of almost all B cell malignancies, including acute lymphoblastic leukemia (ALL), non-Hodgkin lymphoma (NHL), and chronic lymphocytic leukemia (CLL).
New data from the ongoing JCAR014 trial in patients with relapsed or refractory ALL, NHL, or CLL will be presented, with increased patient numbers and longer duration of follow-up compared to previous presentations. The stock is going forward its fifty-two week low with 77.38% and lagging behind from its 52-week high price with -42.73%. Likewise the positive performance for the quarter recorded as 10.93% and for the year was -12.68%, while the YTD performance remained at -9.76%. JUNO has Average True Range for 14 days of 2.04.
Shares of Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC) [Trend Analysis] swings enthusiastically in regular trading session, it a loss of -0.43% to close at $99.56. Ryan & Maniskas, LLP reported that it is investigating potential claims against the board of directors of Anacor Pharmaceuticals, Inc. (ANAC) concerning possible breaches of fiduciary duty and other violations of law related to the Company’s efforts to sell the Company to Pfizer Inc. in a transaction valued at approximately $5.2 billion. Under the terms of the agreement, shareholders of Anacor will receive $99.25 in cash for each share of Anacor common stock. ANAC is going forward its fifty-two week low with 91.46% and lagging behind from its 52-week high price with -36.56%. ANAC last month stock price volatility remained 6.34%.
Novartis AG (NYSE:NVS) [Trend Analysis] retains strong position in active trade, as shares scoring 0.11% to $75.79 in a active trade session, while looking at the shares volume, around 2.19 Million shares have changed hands in this session. Novartis AG (NVS) reported that its head of pharmaceuticals, David Epstein, is to leave the company amid a restructuring that will split his role in two. The Basel, Switzerland-based drug giant stated Mr. Epstein, who is American, had decided to leave the company “to explore new challenges from the U.S.” Chief Executive Joe Jimenez said Mr. Epstein had “steered our pharmaceuticals division through a period of excellence in innovation, execution and improved financial results.” Novartis disclosed Mr. Epstein’s departure as the company announced plans to separate its cancer unit from the rest of the pharmaceuticals business. The firm has institutional ownership of 10.10%, while insider ownership included 9.30%. NVS attains analyst recommendation of 2.40 with week’s performance of 0.87%. Investors looking further ahead will note that the Price to next year’s EPS is 11.71%.